Genetic test for Plavix use may be unneeded: study

December 29, 2011 in Medications

A new study published Wednesday cast doubt on the usefulness of a genetic test for patients taking the anti-coagulant drug Plavix, calling into question last year's FDA warning about the blood thinner.

The study, a new review of 32 previous clinical studies published in the , said the genetic test may not help identify those patients more at risk of a heart attack or other cardiac event.

Plavix, one of the world's top selling drugs, is marketed by US-based Bristol-Myers Squibb and France's Sanofi. It reduces the risk of heart attack and stroke by keeping from sticking together to cause clots.

In 2010, the US Food and Drug Administraion ordered the manufacturers to add a boxed warning to Plavix packets saying the drug may be less effective in preventing heart attacks in people who cannot metabolize it properly.

The FDA said an estimated two to 14 percent of the US population are poor metabolizers who have a certain variant of the gene that makes the CYP2C19 , which converts Plavix to its active form.

The FDA had recommended that doctors prescribe higher doses of Plavix, or clopidogrel, to those patients who had the genetic test and were found not to produce enough of the enzyme.

But researchers led by Michael Holmes at University College London concluded after their new review of studies involving 42,000 patients that those with the did not have more than other patients.

"Despite associations between CYP2C19 genotype, clopidogrel metabolism, and platelet aggregation, this systematic review and meta-analysis does not demonstrate a clinically important association of genotype with ," researchers led by Michael Holmes at University College London said.

The only notable possible exception was in patients with stent thrombosis, they wrote.

"The FDA's warnings on Plavix were premature and were not based on solid science," said Steven Nissen, a cardiologist at the Cleveland Clinic Foundation, in an editorial published in the Journal of the AMA.

Plavix sales totalled $5.4 billion in the first three quarters of 2011, as compared with $4.9 billion in the same period last year.

About 40 million people take the drug worldwide.

(c) 2011 AFP

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Merck ends development of Parkinson's disease drug

(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

Medications created 6 hours ago | popularity 1 / 5 (1) | comments 0

J&J expects 10-plus new drug applications by 2017

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Medications created 7 hours ago | popularity 5 / 5 (1) | comments 0

Experts favor US approval of Merck sleeping pill (Update)

An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Glaxo, US partnering to develop new antibiotics

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...

Medications created May 22, 2013 | popularity not rated yet | comments 0


ACP issues recommendations for management of high blood glucose in hospitalized patients

High blood glucose is associated with poor outcomes in hospitalized patients, and use of intensive insulin therapy (IIT) to control hyperglycemia is a common practice in hospitals. But the recent evidence does not show a ...

Controlling mood through the motions of mitochondria

(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...

Multiple research teams unable to confirm high-profile Alzheimer's study

Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.

Motion quotient: IQ predicted by ability to filter motion (w/ video)

A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...

Scientists discover molecule triggers sensation of itch

Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...

Researchers find common childhood asthma unconnected to allergens or inflammation

Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...